MA48238A1 - New heterocyclic compounds as cdk8 / 19 inhibitors - Google Patents

New heterocyclic compounds as cdk8 / 19 inhibitors

Info

Publication number
MA48238A1
MA48238A1 MA48238A MA48238A MA48238A1 MA 48238 A1 MA48238 A1 MA 48238A1 MA 48238 A MA48238 A MA 48238A MA 48238 A MA48238 A MA 48238A MA 48238 A1 MA48238 A1 MA 48238A1
Authority
MA
Morocco
Prior art keywords
cdk8
inhibitors
heterocyclic compounds
new heterocyclic
compounds
Prior art date
Application number
MA48238A
Other languages
French (fr)
Other versions
MA48238B1 (en
Inventor
Aleksei Leonidovich Mindich
Svetlana Leonidovna Gorbunova
Aleksandra Vladimirovna Popkova
Artsiom Evgenievich Shekhautsou
Andrei Ivanovich Alafinov
Pavel Aleksandrovich Aleshunin
Anton Aleksandrovich Evdokimov
Kirill Vadimovich Zavialov
Mariia Andreevna Kasatkina
Natalia Vladimirovna Kozhemyakina
Anna Sergeevna Kushakova
Elena Aleksandrovna Maksimenko
Mariia Sergeevna Mishina
Mikhail Vladimirovich Rekharsky
Anna Jur'evna Chestnova
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Priority claimed from PCT/RU2018/050089 external-priority patent/WO2019031990A1/en
Publication of MA48238A1 publication Critical patent/MA48238A1/en
Publication of MA48238B1 publication Critical patent/MA48238B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés ayant la formule (i) ou leur sel pharmaceutiquement acceptable ou leur stéréoisomère possédant les propriétés de l'inhibiteur cdk8/19, une composition pharmaceutique contenant ces composés et leur utilisation en tant que préparations médicamenteuses pour traiter différentes maladies ou troubles.The present invention relates to novel compounds having the formula (i) or their pharmaceutically acceptable salt or their stereoisomer having the properties of the cdk8 / 19 inhibitor, a pharmaceutical composition containing these compounds and their use as medicinal preparations for treating various diseases. or troubles.

MA48238A 2017-08-07 2018-07-30 New heterocyclic compounds as cdk8/19 inhibitors MA48238B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017128123A RU2017128123A (en) 2017-08-07 2017-08-07 New heterocyclic compounds as inhibitors of CDK8 / 19
PCT/RU2018/050089 WO2019031990A1 (en) 2017-08-07 2018-07-30 Novel heterocyclic compounds as cdk8/19 inhibitors

Publications (2)

Publication Number Publication Date
MA48238A1 true MA48238A1 (en) 2021-06-30
MA48238B1 MA48238B1 (en) 2021-12-31

Family

ID=65270771

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48238A MA48238B1 (en) 2017-08-07 2018-07-30 New heterocyclic compounds as cdk8/19 inhibitors

Country Status (3)

Country Link
AR (1) AR112675A1 (en)
MA (1) MA48238B1 (en)
RU (1) RU2017128123A (en)

Also Published As

Publication number Publication date
MA48238B1 (en) 2021-12-31
RU2017128123A (en) 2019-02-07
AR112675A1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
MA35576B1 (en) New compounds
MA43169B1 (en) Heterocyclic compounds as pi3k-gamma inhibitors
MA47368B1 (en) N- [4-fluoro-5 - [[(2s, 4s) -2-methyl-4 - [(5-methyl-1,2,4-oxadiazol-3-yl) methoxy] -1-piperidyl] methyl] thiazol-2-yl] acetamide used as an inhibitor of yoga
MA38999A1 (en) New heterocyclic compounds
MA37762A1 (en) N-aryltriazole compounds used as antagonists of lpar
MA33467B1 (en) Primary drugs include insulin-linking facilities
MA27560A1 (en) NOVEL HETEROCYCLIC FLUORGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS AND THEIR USE
MA37764A1 (en) N-alkyltriazole compounds used as antagonists of lpar
MA38227A1 (en) Novel bicyclic compounds and their use as antibacterial agents and inhibitors of? -Lactamase
MA46101B1 (en) Positive allosteric modulators of the m1 muscarinic receptor
MA49956B1 (en) Pyrimidine compounds used as jak kinase inhibitors
TN2014000147A1 (en) (4-PHENYLIMIDAZOL-2-YL) ETHYLAMINE DERIVATIVES USEFUL AS SODIUM CHANNEL MODULATORS
MA27559A1 (en) NOVEL AROMATIC FLUORGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS AND THEIR USE
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MA47469B1 (en) 2- (3- (1h-benzo [d] imidazol-1-yl) propyl) piperidin-3-ol derivatives and similar compounds as inhibitors ready for the treatment of cancer
TNSN08137A1 (en) CARBOXAMIDE DERIVATIVES AS ANTAGONISTS OF MUSCARINIC RECEPTORS
MA46229B1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MA34545B1 (en) CO-CRYSTALS AND SALTS OF CCR3 INHIBITORS
MA37765A1 (en) Substituted pyrazole compounds used as lpar antagonists
EA201992090A1 (en) Deuterated Imidazo [4,5-c] Quinolin-2-One Compounds and Their Use in Cancer Treatment
TN2010000231A1 (en) PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS
MA44965A (en) PYRIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES OF THEM AS AOC3 INHIBITORS
MA52375A1 (en) cdk8/19 inhibitors
MA57022B1 (en) CHONDROGENESIS INDUCTION COMPOUNDS AND COMPOSITIONS